Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions

Current Opinion in Neurobiology

Volumn 36, Issue , 2016, Pages 43-51

  Villemagne, Victor L ^a,b   Okamura, Nobuyuki ^c  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AV 1451 F 18; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; FLUTEMETAMOL F 18; LANSOPRAZOLE C 11; LANSOPRAZOLE F 18; PBB3 C 11; TAU PROTEIN; TRACER; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; BLOOD BRAIN BARRIER; CHRONIC TRAUMATIC ENCEPHALOPATHY; CORTICOBASAL DEGENERATION; DEGENERATIVE DISEASE; EARLY DIAGNOSIS; FRONTOTEMPORAL DEMENTIA; HUMAN; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN AGGREGATION; PROTEIN CONFORMATION; REVIEW; TAUOPATHY; BRAIN; BRAIN INJURY; DIAGNOSTIC IMAGING; METABOLISM; SCINTISCANNING;

AGING; ALZHEIMER DISEASE; BRAIN; BRAIN INJURY, CHRONIC; FRONTOTEMPORAL LOBAR DEGENERATION; HUMANS; NEURODEGENERATIVE DISEASES; NEUROIMAGING; RADIONUCLIDE IMAGING; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS; TAUOPATHIES;

EID: 84941985175     PISSN: 09594388     EISSN: 18736882     Source Type: Journal    
DOI: 10.1016/j.conb.2015.09.002     Document Type: Review

References (87)

1. Chen-Plotkin A.S., Lee V.M., Trojanowski J.Q. TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol 2010, 6:211-220.
2. Rabinovici G.D., Miller B.L. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs 2010, 24:375-398.
3. Seelaar H., Rohrer J.D., Pijnenburg Y.A., Fox N.C., van Swieten J.C. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry 2011, 82:476-486.
4. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55:306-319.
5. Rowe C.C., Ackerman U., Browne W., Mulligan R., Pike K.L., O'Keefe G., Tochon-Danguy H., Chan G., Berlangieri S.U., Jones G., et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008, 7:129-135.
6. Rowe C.C., Pejoska S., Mulligan R.S., Jones G., Chan J.G., Svensson S., Cselenyi Z., Masters C.L., Villemagne V.L. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia. J Nucl Med 2013, 54:880-886.
7. Vandenberghe R., Van Laere K., Ivanoiu A., Salmon E., Bastin C., Triau E., Hasselbalch S., Law I., Andersen A., Korner A., et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010, 68:319-329.
8. Wong D.F., Rosenberg P.B., Zhou Y., Kumar A., Raymont V., Ravert H.T., Dannals R.F., Nandi A., Brasic J.R., Ye W., et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010, 51:913-920.
9. Buee L., Bussiere T., Buee-Scherrer V., Delacourte A., Hof P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000, 33:95-130.
10. Maas T., Eidenmuller J., Brandt R. Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J Biol Chem 2000, 275:15733-15740.
11. Li X., Kumar Y., Zempel H., Mandelkow E.M., Biernat J., Mandelkow E. Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration. Embo J 2011, 30:4825-4837.
12. Hernandez F., Avila J. Tauopathies. Cell Mol Life Sci 2007, 64:2219-2233.
13. Arima K. Ultrastructural characteristics of tau filaments in tauopathies: immuno-electron microscopic demonstration of tau filaments in tauopathies. Neuropathology 2006, 26:475-483.
14. Zempel H., Luedtke J., Kumar Y., Biernat J., Dawson H., Mandelkow E., Mandelkow E.M. Amyloid-beta oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J 2013, 32:2920-2937.
15. Zempel H., Thies E., Mandelkow E., Mandelkow E.M. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci 2010, 30:11938-11950.
16. Braak H., Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl 1998, 53:127-140.
17. Delacourte A., David J.P., Sergeant N., Buee L., Wattez A., Vermersch P., Ghozali F., Fallet-Bianco C., Pasquier F., Lebert F., et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 1999, 52:1158-1165.
18. Braak H., Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997, 18:351-357.
19. Serrano-Pozo A., Frosch M.P., Masliah E., Hyman B.T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011, 1:a006189.
20. Guo J.L., Lee V.M. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem 2011, 286:15317-15331.
21. Mohorko N., Bresjanac M. Tau protein and human tauopathies: an overview. Zdrav Vestn 2008, 77:35-41.
22. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu Rev Neurosci 2001, 24:1121-1159.
23. McKee A.C., Cantu R.C., Nowinski C.J., Hedley-Whyte E.T., Gavett B.E., Budson A.E., Santini V.E., Lee H.S., Kubilus C.A., Stern R.A. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 2009, 68:709-735.
24. Masters C.L., Selkoe D.J. Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med 2012, 2:a006262.
25. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992, 42:631-639.
26. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., Cowie T.F., Dickinson K.L., Maruff P., Darby D., et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
27. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999, 46:860-866.
28. Zempel H., Mandelkow E.M. Linking amyloid-beta and tau: amyloid-beta induced synaptic dysfunction via local wreckage of the neuronal cytoskeleton. Neurodegener Dis 2012, 10:64-72.
29. Ittner L.M., Ke Y.D., Gotz J. Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. J Biol Chem 2009, 284:20909-20916.
30. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999, 45:358-368.
31. Villemagne V.L., Fodero-Tavoletti M.T., Pike K.E., Cappai R., Masters C.L., Rowe C.C. The ART of loss: Aβ imaging in the evaluation of Alzheimer's disease and other dementias. Mol Neurobiol 2008, 38:1-15.
32. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Shaw L.M., Vemuri P., Wiste H.J., Weigand S.D., et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013, 12:207-216.
33. Jack C.R., Knopman D.S., Weigand S.D., Wiste H.J., Vemuri P., Lowe V., Kantarci K., Gunter J.L., Senjem M.L., Ivnik R.J., et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012, 71:765-775.
34. Dutra J.R., Cortes E.P., Vonsattel J.P. Update on hippocampal sclerosis. Curr Neurol Neurosci Rep 2015, 15:592.
35. Crary J.F., Trojanowski J.Q., Schneider J.A., Abisambra J.F., Abner E.L., Alafuzoff I., Arnold S.E., Attems J., Beach T.G., Bigio E.H., et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014, 128:755-766.
36. Villemagne V.L., Furumoto S., Fodero-Tavoletti M.T., Harada R., Mulligan R.S., Kudo T., Masters C.L., Yanai K., Rowe C.C., Okamura N. The challenges of tau imaging. Future Neurol 2012, 7:409-421.
37. Villemagne V.L., Okamura N. In vivo tau imaging: obstacles and progress. Alzheimers Dement 2014, 10:S254-S264.
38. Villemagne V.L., Fodero-Tavoletti M.T., Masters C.L., Rowe C.C. Tau imaging: early progress and future directions. Lancet Neurol 2015, 14:114-124.
39. Wegmann S., Jung Y.J., Chinnathambi S., Mandelkow E.M., Mandelkow E., Muller D.J. Human Tau isoforms assemble into ribbon-like fibrils that display polymorphic structure and stability. J Biol Chem 2010, 285:27302-27313.
40. Sergeant N., Bretteville A., Hamdane M., Caillet-Boudin M.L., Grognet P., Bombois S., Blum D., Delacourte A., Pasquier F., Vanmechelen E., et al. Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Exp Rev Proteom 2008, 5:207-224.
41. Martin L., Latypova X., Terro F. Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem Int 2011, 58:458-471.
42. Spillantini M.G., Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci 1998, 21:428-433.
43. Rosen R.F., Walker L.C., Levine H. 3rd: PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease. Neurobiol Aging 2011, 32:223-234.
44. Ni R., Gillberg P.G., Bergfors A., Marutle A., Nordberg A. Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue. Brain 2013, 136:2217-2227.
45. Scaravilli T., Tolosa E., Ferrer I. Progressive supranuclear palsy and corticobasal degeneration: lumping versus splitting. Mov Disord 2005, 20(Suppl. 12):S21-S28.
46. Khatoon S., Grundke-Iqbal I., Iqbal K. Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains. FEBS Lett 1994, 351:80-84.
47. Mukaetova-Ladinska E.B., Harrington C.R., Roth M., Wischik C.M. Biochemical and anatomical redistribution of tau protein in Alzheimer's disease. Am J Pathol 1993, 143:565-578.
48. Naslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., Buxbaum J.D. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000, 283:1571-1577.
49. Laruelle M., Slifstein M., Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol 2003, 5:363-375.
50. Pike V.W. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci 2009, 30:431-440.
51. Villemagne V.L., Klunk W.E., Mathis C.A., Rowe C.C., Brooks D.J., Hyman B.T., Ikonomovic M.D., Ishii K., Jack C.R., Jagust W.J., et al. Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012, 39:209-219.
52. Shoghi-Jadid K., Small G.W., Agdeppa E.D., Kepe V., Ercoli L.M., Siddarth P., Read S., Satyamurthy N., Petric A., Huang S.C., et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002, 10:24-35.
53. Smid L.M., Kepe V., Vinters H.V., Bresjanac M., Toyokuni T., Satyamurthy N., Wong K.P., Huang S.C., Silverman D.H., Miller K., et al. Postmortem 3-D brain hemisphere cortical tau and amyloid-beta pathology mapping and quantification as a validation method of neuropathology imaging. J Alzheimers Dis 2013, 36:261-274.
54. Taghavi A., Nasir S., Pickhardt M., Heyny-von Haussen R., Mall G., Mandelkow E., Mandelkow E.M., Schmidt B. N'-benzylidene-benzohydrazides as novel and selective tau-PHF ligands. J Alzheimers Dis 2011, 27:835-843.
55. Jensen J.R., Cisek K., Funk K.E., Naphade S., Schafer K.N., Kuret J. Research towards tau imaging. J Alzheimers Dis 2011, 26(Suppl. 3):147-157.
56. Honson N.S., Johnson R.L., Huang W., Inglese J., Austin C.P., Kuret J. Differentiating Alzheimer disease-associated aggregates with small molecules. Neurobiol Dis 2007, 28:251-260.
57. Kemp S, Storey L, Storey J, Rickard J, Harrington C and Wischik C: Ligands for aggregated tau molecules, 2010: International patent 2010/034982.
58. Ono M., Hayashi S., Matsumura K., Kimura H., Okamoto Y., Ihara M., Takahashi R., Mori H., Saji H. Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer's brains. ACS Chem Neurosci 2011, 2:269-275.
59. Watanabe H., Ono M., Kimura H., Matsumura K., Yoshimura M., Okamoto Y., Ihara M., Takahashi R., Saji H. Synthesis and biological evaluation of novel oxindole derivatives for imaging neurofibrillary tangles in Alzheimer's disease. Bioorg Med Chem Lett 2012, 22:5700-5703.
60. Matsumura K., Ono M., Yoshimura M., Kimura H., Watanabe H., Okamoto Y., Ihara M., Takahashi R., Saji H. Synthesis and biological evaluation of novel styryl benzimidazole derivatives as probes for imaging of neurofibrillary tangles in Alzheimer's disease. Bioorg Med Chem 2013, 21:3356-3362.
61. Bolander A., Kieser D., Voss C., Bauer S., Schon C., Burgold S., Bittner T., Holzer J., Heyny-von Haussen R., Mall G., et al. Bis(arylvinyl)pyrazines, -pyrimidines, and -pyridazines as imaging agents for tau fibrils and beta-amyloid plaques in Alzheimer's disease models. J Med Chem 2012, 55:9170-9180.
62. Honson N.S., Jensen J.R., Darby M.V., Kuret J. Potent inhibition of tau fibrillization with a multivalent ligand. Biochem Biophys Res Commun 2007, 363:229-234.
63. Kudo Y, Furumoto S, Okamura N. Benzoxazole derivatives, 2010. U.S. Patent 2010/0021385.
64. Szardenings AK, Zhang W, Kolb HC, Cashion DK, Chen G, Kasi D, Liu C, Sinha A, Wang E, Yu C, et al. Imaging agents for detecting neurological disorders, 2011. Siemens Medical Solutions USA, Inc.: US Patent 2011/0182812 A1.
65. Kudo Y, Susuki M, Suemoto T, Okamura N, Shiomitzu T, Shimazu H. Quinoline derivative as diagnostic probe for disease with tau protein accumulation, 2006. U.S. Patent 7,118,730.
66. Shao X.M., Carpenter G.M., Desmond T.J., Sherman P., Quesada C.A., Fawaz M., Brooks A.F., Kilbourn M.R., Albin R.L., Frey K.A., et al. Evaluation of [11C]N-methyl lansoprazole as a radiopharmaceutical for PET imaging of tau neurofibrillary tangles. ACS Med Chem Lett 2012, 3:936-941.
67. Fawaz M.V., Brooks A.F., Rodnick M.E., Carpenter G.M., Shao X., Desmond T.J., Sherman P., Quesada C.A., Hockley B.G., Kilbourn M.R., et al. High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection. ACS Chem Neurosci 2014, 5:718-730.
68. Maruyama M., Shimada H., Suhara T., Shinotoh H., Ji B., Maeda J., Zhang M.R., Trojanowski J.Q., Lee V.M., Ono M., et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013, 79:1094-1108.
69. Hashimoto H., Kawamura K., Igarashi N., Takei M., Fujishiro T., Aihara Y., Shiomi S., Muto M., Ito T., Furutsuka K., et al. Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology. J Nucl Med 2014, 55:1532-1538.
70. Xia C.F., Arteaga J., Chen G., Gangadharmath U., Gomez L.F., Kasi D., Lam C., Liang Q., Liu C., Mocharla V.P., et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement 2013, 9:666-676.
71. Chien D.T., Bahri S., Szardenings A.K., Walsh J.C., Mu F., Su M.Y., Shankle W.R., Elizarov A., Kolb H.C. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2013, 34:457-468.
72. Vieira M., Saraiva M.J. Transthyretin: a multifaceted protein. Biomol Concepts 2014, 5:45-54.
73. Okamura N., Suemoto T., Furumoto S., Suzuki M., Shimadzu H., Akatsu H., Yamamoto T., Fujiwara H., Nemoto M., Maruyama M., et al. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J Neurosci 2005, 25:10857-10862.
74. Okamura N., Furumoto S., Harada R., Tago T., Yoshikawa T., Fodero-Tavoletti M., Mulligan R.S., Villemagne V.L., Akatsu H., Yamamoto T., et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med 2013, 54:1420-1427.
75. Fodero-Tavoletti M.T., Okamura N., Furumoto S., Mulligan R.S., Connor A.R., McLean C.A., Cao D., Rigopoulos A., Cartwright G.A., O'Keefe G., et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain 2011, 134:1089-1100.
76. Harada R., Okamura N., Furumoto S., Tago T., Maruyama M., Higuchi M., Yoshikawa T., Arai H., Iwata R., Kudo Y., et al. Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. Eur J Nucl Med Mol Imaging 2013, 40:125-132.
77. Fodero-Tavoletti M.T., Furumoto S., Taylor L., McLean C.A., Mulligan R.S., Birchall I., Harada R., Masters C.L., Yanai K., Kudo Y., et al. Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies. Alzheimers Res Ther 2014, 6:11.
78. Villemagne V.L., Furumoto S., Fodero-Tavoletti M.T., Mulligan R.S., Hodges J., Harada R., Yates P., Piguet O., Pejoska S., Dore V., et al. In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur J Nucl Med Mol Imaging 2014, 41:816-826.
79. Okamura N., Furumoto S., Fodero-Tavoletti M.T., Mulligan R.S., Harada R., Yates P., Pejoska S., Kudo Y., Masters C.L., Yanai K., et al. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain 2014, 137:1762-1771.
80. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., Szoeke C., Macaulay S.L., Martins R., Maruff P., et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013, 12:357-367.
81. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
82. Giacobini E., Becker R.E. One hundred years after the discovery of Alzheimer's disease. A turning point for therapy?. J Alzheimers Dis 2007, 12:37-52.
83. Zhang B., Maiti A., Shively S., Lakhani F., McDonald-Jones G., Bruce J., Lee E.B., Xie S.X., Joyce S., Li C., et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci U S A 2005, 102:227-231.
84. Wischik C., Staff R. Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy. J Nutr Health Aging 2009, 13:367-369.
85. Duyckaerts C., Braak H., Brion J.P., Buee L., Del Tredici K., Goedert M., Halliday G., Neumann M., Spillantini M.G., Tolnay M., et al. PART is part of Alzheimer disease. Acta Neuropathol 2015, 129:749-756.
86. Jellinger K.A., Alafuzoff I., Attems J., Beach T.G., Cairns N.J., Crary J.F., Dickson D.W., Hof P.R., Hyman B.T., Jack C.R., et al. PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol 2015, 129:757-762.
87. Marquie M., Normandin M.D., Vanderburg C.R., Costantino I., Bien E.A., Rycyna L.G., Klunk W.E., Mathis C.A., Ikonomovic M.D., Debnath M.L., et al. Validating novel tau PET tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 2015, 10.1002/ana.24517.